We are devoted to strengthening emerging pharmaceutical markets. To this end, we commit to upholding essential principles in all of our dealings with clients. Our Client Charter is our promise to you that ...
Our Quality Edge is how we blend Empathy, Reliability and Responsiveness to deliver exceptional service to all our clients.
We Partner with Clients to execute Outcomes Research in emerging markets.
We develop results-driven market access solutions for clients in emerging markets.
Market Access Solutions
Innovative Access Strategies
Our Quality Edge
Kaiser survey finds majority voters doubt Trump’s drug price gambits phrmaccess.com/x/s7 pic.twitter.com/kNqBLjiPYF
About 2 weeks ago from Carapinha & Company's Twitter
Hospitals mark-up medicines 700%-1000% in the US phrmaccess.com/x/s9 pic.twitter.com/N2feYuuKTg
Trump’s “American Patients First” plan actually has teeth, if implemented. phrmaccess.com/x/rz pic.twitter.com/Bs0DZFFIMe
Policy coherence and uniformity across Europe will support future generic pharma growth phrmaccess.com/x/s0 pic.twitter.com/OtCzfs6dZ1
NHS UK to treat ALL children with Novartis Kymriah: CAR-T therapy. phrmaccess.com/x/rw pic.twitter.com/bd5mKDfiht
Generic and Biosimilar Uptake Must Be Fostered Through Policy and Education phrmaccess.com/x/rr pic.twitter.com/RhG21ukLZz
About 3 weeks ago from Carapinha & Company's Twitter
Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study phrmaccess.com/x/rp pic.twitter.com/nnNkHgMAqy
Price control in India, ad-hoc regulatory changes may hamper pharma sector growth: Pfizer phrmaccess.com/x/rh pic.twitter.com/bmJvvNi0lt
Insulin’s High Cost Leads To Lethal Rationing phrmaccess.com/x/ri pic.twitter.com/v9WFGyLdbq
Why all the negativity around NHI in South Africa? | Carapinha & Company phrmaccess.com/x/rb pic.twitter.com/0HIyKBnnVl
Oklahoma is implementing a new program that only pays big pharma full price if their drugs work phrmaccess.com/x/rc pic.twitter.com/IydZMMum7c
What price biotech innovation? phrmaccess.com/x/r7 pic.twitter.com/bCw6n6RHW0
Cancer drug prices set to drop in China phrmaccess.com/x/r8 pic.twitter.com/XSuhsminSr
Value-Based Pricing of New Technologies phrmaccess.com/x/qz pic.twitter.com/TrT0tsrpBO
Last month from Carapinha & Company's Twitter
Health Dept hits back at foundation over NHI criticism phrmaccess.com/x/r2 pic.twitter.com/onFv55lYS9